Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh
Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi
Unaudited Financial Results for the Quarter/Half Year Ended 30th Sept, 2011

(Rs. Crores)

Particulars	Quarter ended 30/09/2011	Corresponding Quarter in the previous year ended 30/09/2010	Half Year ended 30/09/2011	Corresponding Half year in the previous year ended 30/09/2010	Previous Accounting Year ended 31/03/2011
	Unaudited	**Unaudited**	**Unaudited**	**Unaudited**	**Audited**
a) Gross Sales	215.19	161.43	420.66	301.58	675.30
Less : Excise Duty	(19.60)	(14.57)	(38.88)	(27.24)	(59.28)
Net Sales/Income from Operations	195.59	146.86	381.78	274.34	616.02
(b)Other Operating Income	3.00	0.59	5.68	0.91	19.16
1. Total Income	**198.59**	**147.45**	**387.46**	**275.25**	**635.18**
2. Expenditure					
a) (Increase)/Decrease in stock in trade and work in progress	(17.59)	(46.97)	(82.41)	(63.16)	(89.78)
b) Consumption of Raw Materials	157.24	151.03	355.60	257.49	541.09
c) Employees Cost	5.72	4.00	10.45	7.46	16.93
d) Depreciation & Amortisations	7.76	4.36	15.51	8.71	17.69
e) Other Expenditure	10.64	9.69	19.44	18.02	39.81
f) Total	**163.77**	**122.11**	**318.59**	**228.52**	**525.74**
3. Profit from Operations before Other Income, Interest & Exceptional Items	**34.81**	**25.34**	**68.87**	**46.73**	**109.44**
4. Other Income					
5. Profit before Interest & Exceptional Items (3 + 4)	**34.81**	**25.34**	**68.87**	**46.73**	**109.44**
6. Interest	15.90	6.54	30.04	14.43	40.76
7. Profit after interest but before Exceptional Items (5-6)	**18.92**	**18.80**	**38.83**	**32.30**	**68.68**
8. Exceptional Items	-				-
9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)	**18.92**	**18.80**	**38.83**	**32.30**	**68.68**
10. Tax expenses	4.53	4.51	9.27	7.48	15.81
11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)	**14.38**	**14.29**	**29.57**	**24.82**	**52.87**
12. Extra Ordinary Items					-
13. Net Profit (+)/ Loss(-) for the period (11-12)	**14.38**	**14.29**	**29.57**	**24.82**	**52.87**
14. Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89	61.89	61.89
15. Reserve excluding Revaluation Rserves as per balance sheet of previous accounting year	-	-	-	-	317.11
16. Earnings Per Share (EPS)					
- Basic EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.32	2.31	4.78	4.93	9.43
- Diluted EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.32	2.31	4.78	4.93	9.43
- Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.32	2.31	4.78	4.93	9.43
- Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.32	2.31	4.78	4.93	9.43
17. Public Shareholding :					
- Number of Shares	37945559	38346994	37945559	38346994	38257907
- Percentage of Shareholding	61.31	61.96	61.31	61.96	61.81
18. Promoters and Promoter Group Shareholding (non-encumbered) :					
- Number of shares	23946455	23545020	23946455	23545020	23634107
- Percentage of shares (as a % of the to total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the to total share capital of the company)	38.69	38.04	38.69	38.04	38.19

(Rs. In crores)

Statement of Assets & Liabilities :	As at 30th Sept 11 (Unaudited)	As at 30th Sept 10 (Unaudited)
Shareholders Funds :		
Share Capital	61.89	61.89
Reserves & Surplus	346.55	306.35
Loan Funds	504.57	373.42
Deferred Tax Liability	11.25	8.67
Total	924.26	750.33
Fixed Assets	308.04	210.82
Investments	3.16	1.99
Current Assets, Loans & Advances:		
Inventories	415.87	298.48
Sundry Debtors	254.53	246.25
Cash & Bank Balances	26.79	32.68
Loan & Advances	76.85	44.31
Less : Current Liabilities & Provisions :	286.05	150.64
Miscellaneous Expentiure	125.07	66.44
(to the extent not written off or adjusted)		
Total	924.26	750.33

Notes :

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 12th November, 2011 and the same have been undergone Limited Review by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.

2. The Company successfully filed its first Drug Master Files (DMF) to Japanese PMDA, thereby adding to the regulatory strength. The company has 38 DMF filed across US, EU, Japan and Canada.

3. The Company has received an Official accredition from Japan's Ministry of Health, Labour and Welfare, enabling it to manufacture and supply Cephalosporin Non-Sterile drugs to the Japanese market. The five year accredition has been awarded to Parabolic's manufacturing site at Derabassi in Punjab and is in accordance with Article 13-3 of Phramaceutical Affairs Act, which classified Parabolic as a certified foreign drug manufacturer.

4. During the period under review, the Company also faced various audits from different MNCs and is in dicussion for future business tie-ups and alliances.

5. The company has also filed one process patent application with Indian Patent Office for the Anti-diabetic Molecule and till date 17 Patent applications have been filed.

6. There were no investor complaints pending at the beginning of the quarter. Only five complaints were received during the quarter ended 30th September 2011 and the same has been resolved and there was no investor complaint pending at the end of the quarter.

7. The above financials results are on stand alone basis.

8. There is not more than one reportable segment, hence, information as per AS-17 is not required to be be disclosed.

9. Figures of the previous year have been rearranged/regrouped wherever necessary.

For Parabolic Drugs Ltd.

Sd/-
Pranav Gupta
Managing Director

Place : Chandigarh
Date : 12th November, 2011